Altimmune aims to build Momentum in obesity

Novo Nordisk’s Wegovy has revolutionised the treatment of obesity in the short time it has been on the market, and Lilly’s Mounjaro is expected to do even better if – or, more likely, when – it gets the nod this year.

Of the many groups following these two colossi, one of the hottest hopes is Altimmune, whose incretin pemvidutide is due to yield interim data from a mid-stage trial towards the end of March.